

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 January 2004 (15.01.2004)

PCT

(10) International Publication Number
WO 2004/004781 A1

(51) International Patent Classification⁷: **A61K 47/00,**
38/37

STEVENS, John [GB/GB]; J.D.S. Consulting, 18 Wood-
land Rd, Thornton Heath CR7 7LP (GB).

(21) International Application Number:
PCT/EP2003/007349

(74) Agent: GRUBB, Philip; Novartis AG, Corporate Intel-
lectual Property, CH-4002 Basel (CH).

(22) International Filing Date: 8 July 2003 (08.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM,
TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(30) Priority Data:
60/394,699 9 July 2002 (09.07.2002) US
60/394,612 9 July 2002 (09.07.2002) US
60/394,611 9 July 2002 (09.07.2002) US

(84) Designated States (*regional*): Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicants (*for all designated States except US*): SAN-
DOZ GMBH [AT/AT]; Biochemiestrasse 10, A-6250
Kundl (AT). GRANDIS BIOTECH GMBH [DE/DE];
Grünstrasse 18, 79232 March-Hugstetten (DE).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): ¹⁸⁰~~BETZ, Michael~~
[DE/CH]; Jägerstrasse 1, CH-8200 Schaffhausen (CH).
CHX

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: LIQUID FORMULATIONS WITH HIGH CONCENTRATION OF HUMAN GROWTH HORMONE (hgh) COMPRIS-
ING 1,2-PROPYLENE GLYCOL

(57) Abstract: The present invention relates to liquid formulations of human growth hormone (hGH, somatropin) which are storage
stable, show reduced or no crystallization on storage and are suitable for administration to the human or animal body. More particu-
larly, the invention relates to liquid formulations of human growth hormone which are stable and exhibit minimal or no crystallization
when stored at least for a time at temperature above refrigeration temperatures.

WO 2004/004781 A1